Pear Therapeutics

The new analysis of a Pear Therapeutics-based randomized controlled trial came alongside another investigation that spotted early signs of treatment dropout.

Also: Google promises not to use Fitbit data for targeted advertising; Renalytix AI details its international IPO; New food tracking app relies on machine learning.

The PBM will be able to offer and administer benefit coverage for addiction-focused digital therapeutics. 

Large health tech customers are more cautious and overwhelmed than ever, which means that many younger digital health startups will face an uphill battle selling their products in the months to come.

The new tool will be released for limited distribution and will provide multimodal neurobehavioral interventions. 

Dr. Yuri Maricich, chief medical officer at Pear Therapeutics, speaks on his company's experience bringing a digital therapeutic product through the regulator's experimental program for health software.

Somryst, a prescription digital therapeutic combining cognitive behavioral therapy and personalized sleep restriction, is the first software product to put the FDA's early Precertification Program framework through its paces. 

Also: Doctor on Demand-powered benefit goes live for Walmart associates; Samsung, Sleep Number's CES announcements.

New agreements with five different tech companies and research organizations aim to expand and flesh out the digital therapeutics maker's product pipeline.

The industry is better off viewing the the floundering deals between Onduo and Sanofi, Proteus and Otsuka, and Pear and Sandoz as a learning opportunity.